RELAPSED/ REFRACTORY T-CELL MALIGNANCIES

Clinical trials for RELAPSED/ REFRACTORY T-CELL MALIGNANCIES explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/ REFRACTORY T-CELL MALIGNANCIES trials appear

Sign up with your email to follow new studies for RELAPSED/ REFRACTORY T-CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New drug cocktail tested for rare, aggressive cancers

Disease control Completed

This early-stage study tested whether a combination of four existing drugs could be safely given to adults with rare T-cell cancers that had returned or stopped responding to standard treatments. The main goal was to find the safest dose and understand the side effects. Researche…

Matched conditions: RELAPSED/ REFRACTORY T-CELL MALIGNANCIES

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 19, 2026 14:55 UTC

RELAPSED/ REFRACTORY T-CELL MALIGNANCIES

Get alerted when new RELAPSED/ REFRACTORY T-CELL MALIGNANCIES trials appear

New drug cocktail tested for rare, aggressive cancers